Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | 阶段
第二阶段
|
Date Added 2023-03-15 |
地点
英国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Atezolizumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | 阶段
第二阶段
|
Date Added 2023-03-16 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Fruquintinib, Tislelizumab, Vitamin E |
标签
MSS/ MMRp
|
| NCT ID NCT05217446 |
TitleA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK ) | 阶段
第二阶段
|
Date Added 2022-02-01 |
地点
Arizona, United States
California, United States Florida, United States Illinois, United States Minnesota, United States New York, United States Tennessee, United States Texas, United States 澳大利亚 比利时 加拿大 Czechia 丹麦 法国 德国 意大利 荷兰 挪威 波兰 Slovakia 西班牙 瑞典 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
encorafenib, Braftovi, Erbitux, Keytruda |
标签
MSI-H/ MMRd
|
| NCT ID NCT04895722 |
TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | 阶段
第二阶段
|
Date Added 2021-05-20 |
地点
Florida, United States
Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States 比利时 加拿大 Colombia Costa Rica 丹麦 Estonia 法国 德国 希腊 Guatemala Hungary 意大利 大韩民国 Lithuania 荷兰 波兰 Romania Russian Federation 西班牙 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda |
标签
MSI-H/ MMRd
|
| NCT ID NCT04730544 |
TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE ) | 阶段
第二阶段
|
Date Added 2021-01-29 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT04008030 |
TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW ) | 阶段
第三阶段
|
Date Added 2019-07-05 |
地点
California, United States
Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States 阿根廷 澳大利亚 Austria 比利时 巴西 加拿大 智利 中国 Czechia 丹麦 法国 德国 希腊 Ireland 意大利 日本 荷兰 挪威 波多黎各 Romania 西班牙 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT03667170 |
TitleKN035 for dMMR/MSI-H Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2018-09-12 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT02997228 |
TitleCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | 阶段
第三阶段
|
Date Added 2016-12-20 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
暂停
|
药物
Atezolizumab, fluorouracil, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT05239741 |
TitleStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | 阶段
第三阶段
|
Date Added 2022-02-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-08-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
PD-1 antibody + cox inhibitor |
标签
MSI-H/ MMRd
|
